The hourly bid/ask variability has never (in recent history) been anything to worry about with this stock. Market makers are just vying for positions. All is well. don't be surprised to see nice upside close.
4Q catalysts coudl push Celldex to $50 is more like it Weight. Don't be surprised if Celldex outperforms your conservative long sentiment. With not one but two late-stage high-probability of success targeted immunotherapies 100% owned getting ready for prime-time, this soon to be commercial biotech has lots of room to run- and well past $40 I suspect. Don't forget the deep pipeline that includes also not one but two with catalysts reading out in the near-term (CDX-1127 and CDX-1135) that dwarf the lead compounds in terms of potential peak sales. Stick with Celldex and buy more here on the dip if you can (I did). This consolidation is actually going to work out in favor of pps appreciation in the 4Q. We are going higher gentlemen on the back of strong science and better medicines.
The data releases in November will cause CLDX to trade at least in the $40s by the end of that month, and as more and more people realize that CLDX is a potential gold mine the price will steadily increase because people will want to own shares of the CLDX gold mine.